By Christiana Sciaudone
- PerkinElmer (NYSE:PKI) rose 3.4% after forecasting growth in reported revenue and organic revenue of about 12% for the second quarter thanks to Covid-19 testing.
Shares are trading at a near-record, up about 60% since hitting a 2020 low in March.
Demand for the company’s RT-PCR and serology tests, RNA extraction systems and kits, and automated liquid handling instrumentation was robust, PerkinElmer said in a statement. Coronavirus-related sales contributed about $190 million of revenue in the second quarter ended July 5.
Revenue for the second quarter of the previous period totaled $722.5 million, representing growth of 3% compared to a year earlier.
PerkinElmer releases results on July 28.
